## The federal government closes in on healthcare pricing transparency—here's what digital health players are doing about it

**Article** 





**The news:** The Biden administration is doubling down on drug pricing transparency with a new plan to lower drug prices.

- This will allow the CMS to negotiate drug prices, limit price increases, promote industry competition, and support medical innovations that can combat high healthcare costs.
- The <u>29-page plan</u> also includes initiatives for capping **Medicare** members' out-of-pocket costs, shortening drug manufacturers' exclusivity periods, and reducing regulatory barriers for lower-priced generic medications.

**Behind the decision:** Back in January, the federal government rolled out its hospital price transparency rule that requires hospitals to fully disclose the prices they negotiate with payers and the cost of a medical service before a patient receives it.

Why now? Drug prices have reached an all-time high.

- At the beginning of this year, pharma giants like **Bristol Myers Squibb**, **Pfizer**, and **Abbvie** raised the US list prices of more than 500 drugs, <u>according to</u> an analysis by healthcare research firm 46brooklyn.
- Retail prices for the most common prescription drugs are increasing twice as quickly as inflation, according to AARP's 2021 Rx Price Watch report.
- The price hikes came as pharma companies are reeling from lower demand for some drugs due to the pandemic-induced drop in doctor visits.

Why it matters: Drug unaffordability and lack of pricing transparency are top contributors of low medication adherence.

 18.7% of US adults said they delayed a refill, and 16.4% said they rationed medication to extend a prescription because of drug costs, per GoodRx's 2021 Medication Debt Survey.

## Changes in Medication Adherence Due to Prescription Drug Cost According to US Adults\*, Feb 2021 % of respondents Delayed refill after running out of meds Rationed your meds to extend a prescription 16.4% Switched to a more affordable alternative 13.0% Stopped taking a medication entirely 11.5% 2.0% Purchased meds from another country Note: n=1,029 ages 18+; in the past year; 38.8% of respondents have made at least one of the changes; "among those who take a prescription medication for an ongoing condition such as diabetes or high blood pressure Source: GoodRx, "Medication Debt Survey" conducted by Google Surveys as cited in company blog, March 22, 2021

The opportunity: Digital health players are already one step ahead of the game.

- At the same time, Athenahealth's digital provider support company Epocrates is expanding
  its partnership with patient access solutions company ConnectiveRx. deliver point-of-care
  messages to patients regarding drug cost-savings options
- And it's not the first digital health player to start chipping away at healthcare pricing transparency.
- For example, **GoodRx** recently partnered with e-prescription company **Surescripts** to give its users access to discount price information. And healthcare price transparency startup **Turquoise Health** has been building out its platform to let consumers compare costs of care and insurance rates for the most affordable healthcare products and services in their area.





